Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
- Andrea Wang-Gillam
- , Kian Huat Lim
- , Robert McWilliams
- , Rama Suresh
- , Albert C. Lockhart
- , Amberly Brown
- , Marcus Breden
- , Jad I. Belle
- , John Herndon
- , Savannah J. Bogner
- , Katrina Pedersen
- , Benjamin Tan
- , Nicholas Boice
- , Abhi Acharya
- , Mina Abdiannia
- , Feng Gao
- , Harry H. Yoon
- , Mojun Zhu
- , Nikolaos A. Trikalinos
- , Lee Ratner
- Section of Molecular Oncology & Developmental Therapeutics
- Institute of Clinical and Translational Sciences (ICTS)
- Bursky Center for Human Immunology and Immunotherapy
- Siteman Cancer Center
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- DBBS - Cancer Biology
- DBBS - Immunology
- DBBS - Molecular Cell Biology
- Section of Medical Oncology
- Division of Public Health Sciences
- Division of Oncology
- DBBS - Molecular Genetics and Genomics
- DBBS - Molecular Microbiology and Microbial Pathogenesis
- Division of General Surgery
- Section of Hepatobiliary-Pancreatic & Gastrointestinal Surgery
Research output: Contribution to journal › Article › peer-review
90
Link opens in a new tab
Scopus
citations